Caladrius Biosciences, Inc. (Caladrius, formerly NeoStem) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.

Through developing and manufacturing cell therapies to treat those in need, we are dedicated to enabling people to enjoy a healthier span of life. Our overall vision includes commitment to the following:

  • We will be recognized for our culture of respect, our teamwork, and our patient- and customer-centric mindset.
  • We will drive the evolution of the cell therapy industry.
  • We will generate industry-leading growth through our significant operational scale, our innovation and our executional excellence.
  • We will set ourselves apart in the industry, creating value by allowing our people, shareholders and company to prosper.
  • We will bring significant life-improving medical treatments to patients.
Contact Caladrius Biosciences, Inc.
908.842.0100
Visit Website